Currently available pharmacological treatments for schizophrenia derive their activity mainly
by directly modulating the D2 receptor. This mode of action can alleviate the positive …

The introduction of atypical antipsychotics (AAPs) since the discovery of its prototypical drug
clozapine has been a revolutionary pharmacological step for treating psychotic patients as …

Schizophrenia is a mental disorder that affects approximately 1–2% of the population and
develops in early adulthood. The disease is characterized by positive, negative, and …

All currently efficacious antipsychotic drugs have as part of their mechanism the ability to
attenuate some or all of the signaling through the dopamine D 2 receptor. More recently, the …

Despite the use of antipsychotics to treat schizophrenia for the last several decades, little
was understood about their molecular mechanisms of action. In this review, we discuss …

Historically, pharmacotherapy for schizophrenia was mainly focused on finding drugs to treat
psychotic symptoms only, without addressing other crucial domains of the disorder such as …

Schizophrenia has been conceptualized as a neurodevelopmental disorder with synaptic
alterations and aberrant cortical–subcortical connections. Antipsychotics are the mainstay of …

Since the introduction of chlorpromazine and throughout the development of the new-
generation antipsychotic drugs (APDs) beginning with clozapine, the D 2 receptor has been …

In spite of the significant impact that the serendipitous discovery of drugs with antipsychotic
properties had on the care of patients with psychotic disorders, there are significant …

Schizophrenia is a complex and serious disorder which affects some 0.5-1.0% of the
population. The disease generally begins in adolescence. This early onset, together with the …